pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TEVA PHARMACEUTICAL INDUSTRIES LTD ($TEVA) · news · pharmadog
← back to TEVA PHARMACEUTICAL INDUSTRIES LTD
News mentioning $TEVA
63
stories
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
6d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
6d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
9d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
15d
Novartis ends BioArctic pact; Two VC firms raise inaugural funds
endpoints
15d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
16d
Teva ends trial of one of its original line-up of innovative meds over futility
fiercebiotech
20d
UK lands £500M in biopharma pledges; Teva to shutter New Jersey site
endpoints
Oct 15, 26
Webinar: The China question: Can US biotechs lead as investment heads east?
biospace
Oct 12, 26
First Tracks climbs on ‘impressive’ celiac study data
biopharma dive
Oct 8, 26
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
fiercebiotech
Oct 6, 26
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
Oct 1, 26
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 2, 26
Teva says gluten challenge study succeeds in celiac disease
endpoints
Sep 2, 26
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
biopharma dive
Sep 2, 26
Teva autoimmune antibody notches ph. 2 win in celiac disease
fiercebiotech
Sep 1, 26
Mid-cap biotechs join Trump’s latest round of drug pricing deals
biopharma dive
Sep 1, 26
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Aug 31, 26
STAT+: Trump strikes nine more deals with drugmakers to lower prices
stat
Aug 31, 26
STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more
stat
Aug 28, 26
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
biospace
Aug 28, 26
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
endpoints
Aug 28, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 28, 26
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
fiercebiotech
Aug 27, 26
STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
stat
Aug 26, 26
STAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more
stat
Aug 25, 26
STAT+: Sword Health to acquire Headspace, according to filing
stat
← prev
page 1 of 3
next →